NCT00885248

Brief Summary

In suspecting pancreatic cancer, dynamic phase pancreatic CT is the most effective tool in diagnosis and staging. In addition, magnetic resolution image, endoscopic ultrasonography, endoscopic retrograde pancreatography, angiography can be performed. After introduction of functional image, PET has been suggested in the role of diagnosis and staging of pancreatic cancer. Furthermore, recently fused images of PET and CT were available. In this study, the researchers evaluate the role of integrated PET-CT in patients with pancreatic cancer and analysis the cost-effectiveness of the integrated PET-CT.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2009

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 20, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 21, 2009

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2009

Completed
Last Updated

April 21, 2009

Status Verified

April 1, 2009

Enrollment Period

10 months

First QC Date

April 20, 2009

Last Update Submit

April 20, 2009

Conditions

Pancreatic Cancer

Keywords

pancreatic cancerintegrated PET-CT

Outcome Measures

Primary Outcomes (1)

  • Staging of pancreatic cancer

    6 months after study start

Secondary Outcomes (1)

  • Diagnosis of pancreatic cancer

    6 months after study start

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The suspects of pancreatic cancer to visit Asan Medical Center in South Korea

You may qualify if:

  • Pancreatic mass suspicious of pancreatic cancer
  • No comorbidity, expected life expectancy less than 6 months
  • Consent this study in letter

You may not qualify if:

  • Refuse diagnostic and staging work-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asan Medical Center

Seoul, 138-736, South Korea

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 20, 2009

First Posted

April 21, 2009

Study Start

January 1, 2009

Primary Completion

November 1, 2009

Study Completion

December 1, 2009

Last Updated

April 21, 2009

Record last verified: 2009-04

Locations

KR(1)